艾塞那肽联合基础胰岛素增强内源性GLP-1分泌反应
这项随机试验将2型糖尿病成人分为8周基础胰岛素组、基础胰岛素联合赖脯胰岛素组、基础胰岛素联合艾塞那肽组,在停药后行2小时口服葡萄糖耐量试验。结果显示,艾塞那肽联合基础胰岛素组在30、60、90分钟及基线校正AUC的GLP-1水平最高,而胰高血糖素和GIP分泌无组间差异。
要点
- 艾塞那肽联合基础胰岛素停药后,口服葡萄糖负荷后内源性GLP-1分泌增强。
- 该联合治疗对胰高血糖素和GIP的分泌反应无显著影响。
- 空腹GLP-1水平在各治疗组间无差异。
核心结论
- 艾塞那肽联合基础胰岛素治疗可增强停药后口服葡萄糖负荷时的内源性GLP-1分泌反应。
- 该联合治疗对胰高血糖素和GIP的分泌无差异性影响。
研究设计与样本
- 随机对照试验,纳入2型糖尿病成人,随机分为8周基础胰岛素甘精胰岛素组(n=30)、甘精胰岛素联合每日三次赖脯胰岛素组(n=32)、甘精胰岛素联合每日两次艾塞那肽组(n=31)。
- 在基线和8周停药后行2小时口服葡萄糖耐量试验,每30分钟测量循环激素浓度。
主要发现
- 8周口服葡萄糖耐量试验中,艾塞那肽联合基础胰岛素组在30分钟(P=.037)、60分钟(P=.007)、90分钟(P=.039)的基线校正GLP-1最高。
- 艾塞那肽联合基础胰岛素组在负荷后30和60分钟的GLP-1浓度高于其他治疗组(均P<.05)。
- 8周时基线校正GLP-1的曲线下面积在艾塞那肽联合基础胰岛素组最高(P=.037)。
- 胰高血糖素和GIP的基线校正曲线下面积组间比较均无统计学差异(P=NS)。
- 空腹GLP-1水平组间无差异。
临床怎么用
- 对于接受基础胰岛素治疗的2型糖尿病患者,加用艾塞那肽可能增强内源性GLP-1分泌反应,但需结合临床情况个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prolonged exposure to hormonal therapy can affect endogenous hormone secretion. In type 2 diabetes (T2DM), glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being administered in combination with therapies targeting additional hormones (including glucose-dependent insulinotropic polypeptide [GIP], glucagon, and insulin). However, little is known on how they affect endogenous GLP-1 secretion. OBJECTIVE: We sought to evaluate the effect of exenatide b.i.d on endogenous secretion of GLP-1, GIP, and glucagon in patients treated concurrently with basal insulin. DESIGN/SETTING/PATIENTS: In this trial, adults with T2DM were randomized to 8-week treatment with basal insulin glargine (Glar; n = 30), glargine plus thrice-daily lispro (Glar/Lispro; n = 32), or glargine plus twice-daily exenatide (Glar/Exe; n = 31). OUTCOME: Endogenous secretion of glucagon, GIP and GLP-1 was assessed on 2-hour oral glucose tolerance test (OGTT) at baseline and after stopping therapy at 8 weeks, during which their circulating concentrations were measured every 30 minutes. RESULTS: There were no differences between groups in response profiles of glucagon and GIP. While there were no differences in fasting GLP-1, Glar/Exe induced higher GLP-1 concentrations than the other treatments at 30 and 60 minutes post-challenge at 8 weeks (both P < .05). On the 8-week OGTT, baseline-adjusted GLP-1 was the highest in Glar/Exe at each of 30 minutes (P = .037), 60 minutes (P = .007), and 90 minutes (P = .039). Unlike the respective between-group comparisons of baseline-adjusted area-under-the-curve (AUC) for glucagon and GIP (both P = NS), baseline-adjusted AUCGLP-1 at 8 weeks was the highest in Glar/Exe (P = .037). CONCLUSION: When combined with basal insulin therapy, exenatide induces an enhanced post-challenge endogenous GLP-1 secretory response following its cessation, with no differential effect on glucagon and GIP secretion.
引用
- Parikh M, Pu J, Shen J, et al. Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. J Clin Endocrinol Metab. 2026. PMID: 41604435. doi:10.1210/clinem/dgag033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。